Cognitive dysfunction is a central feature of schizophrenia and leads to significant impacts on patient function and quality of life. As such, addressing cognitive impairment is a major unmet medical need in the development of therapies for people with schizophrenia.
Cogstate supports sponsors in these efforts by providing valid, sensitive, and reliable digital cognitive assessments that comprehensively evaluates cognitive domains of relevance to people with schizophrenia, while offering a significant reduction in patient and trial burden compared to other assessment tools.
Please fill out the form below to download the fact sheet and learn more.
